GSK outlines UK manufacturing investment and product divestment plans

19 July 2017

The UK’s largest pharma company, GlaxoSmithKline (LSE: GSK) today announced plans for the company in terms of investments and divestments over the next several years.

These include both investments for respiratory and HIV medicines manufacturing in the UK and strategic reviews, including the sale of several products and a proposal to close a UK manufacturing site, GSK noted.

Between now and 2020, the company plans to invest more than £140 million ($182 million) at its Ware, Hertfordshire, Barnard Castle, Co Durham and Montrose, Scotland, sites. The investments will support expansion of manufacturing for respiratory and HIV medicines. This new investment is in addition to the £275 million announced last year and investment of over £1.2 billion in UK manufacturing since 2012.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK